Targacept to Report First Quarter 2010 Financial Results on May 5, 2010
Winston-Salem, NC
April 28, 2010
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it will report financial results for the first quarter ended March 31, 2010 on Wednesday, May 5, 2010, after the U.S. financial markets close.
Management will discuss the first quarter results, provide an update on the company’s product development programs and business activities and discuss expectations for the future via conference call at 5:00 p.m. Eastern Daylight Time on Wednesday, May 5, 2010. The conference call may be accessed by dialing (800) 299-7928 for domestic participants and (617) 614-3926 for international callers (reference passcode 84591908). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Daylight Time on May 5, 2010 through May 19, 2010 by dialing (888) 286-8010 for domestic callers and (617) 801-6888 for international callers (reference passcode 41944133).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the call.
About Targacept
Targacept is a clinical-stage biopharmaceutical company with a vision of building health and restoring independence for patients. Targacept has leveraged its leadership position in NNR research to build a diverse pipeline of NNR Therapeutics(TM) in development to treat an array of central nervous system diseases and disorders, including major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer’s disease and cognitive dysfunction in schizophrenia. In addition, Targacept has alliances with the global pharmaceutical companies AstraZeneca and GlaxoSmithKline. Targacept’s news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, SVP, Finance and Administration and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 362-3087
Email: linnmich@comcast.net
Back to Newsroom